Immunophenotypic analysis of acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 16, Issue 2, 2002, Pages 245-299

  Riley, Roger S ^a   Massey, Davis ^a   Jackson Cook, Colleen ^a   Idowu, Michael ^a   Romagnoli, Gina ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA ANTIGEN; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW; CANCER DIAGNOSIS; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE REGENERATION; ADULT; B LYMPHOCYTE; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CANCER STEM CELL; CELL LINEAGE; CHEMISTRY; CHILD; CLASSIFICATION; FORECASTING; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INSTRUMENTATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CHILD; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; FLUORESCENT DYES; FORECASTING; HLA-DR ANTIGENS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TUMOR STEM CELLS; HUMANS;

EID: 0036080377     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00004-7     Document Type: Review

References (229)

1. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia
2. New methodologic approaches for immunophenotyping acute leukemias
3. Immunophenotyping of leukemia
4. Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease
5. Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias
6. Acute lymphoblastic leukemia
7. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: Current status and future directions
8. Immunophenotyping leukemias: The new force in hematology
9. Flow cytometry in the diagnosis of acute leukemia
10. Validation and quality control of immunophenotyping in clinical flow cytometry
11. Human T lymphocyte differentiation antigens: Effects of blood sample storage on Leu antibody binding
12. Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting
13. Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry
14. Detection of intracytoplasmic immunoglobulin by flow cytometry in B-cell malignancies
15. Flow cytometric detection of cytoplasmic antigens in acute leukemias: Implications for lineage assignment
16. Demonstration of cytoplasmic and nuclear antigens in acute leukaemia using flow cytometry
17. Evaluation of different fixation-permeabilization methods for simultaneous detection of surface cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines
18. Flow cytometric identification of intracellular antigens: Detection of minimal residual leukemia
19. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes
20. Flow cytometric detection of intracellular myeloperoxidase CD3 and CD79a. Interaction between monoclonal antibody clones fluorochromes and sample preparation protocols
21. Flow cytometric analysis of intracellular myeloperoxidase and lactoferrin in leukemia diagnosis
22. Intracellular markers in acute myeloid leukemia diagnosis
23. A novel method of microwave treatment for detection of cytoplasmic and nuclear antigens by flow cytometry
24. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells
25. Detection of membrane and intracellular antigens by flow cytometry following ORTHO PermeaFix fixation
26. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia
27. Flow-cytometric detection of terminal deoxynucleotidyl transferase and other intracellular antigens in combination with membrane antigens in acute lymphatic leukemias
28. Clinical applications of flow cytometry. Immunologic methods for measuring cell membrane and cytoplasmic antigens
29. Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry
30. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis
31. CD45 gating for routine flow cytometric analysis of human bone marrow specimens
32. Gating strategy for immunophenotyping of leukemia and lymphoma
33. Immunophenotyping of acute leukemia: Utility of CD45 for blast cell identification
34. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy
35. Marker discrepancy as a diagnostic criterion for lymphoid neoplasms
36. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis
37. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia
38. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression
39. PreB1 (CD10-) acute lymphoblastic leukemia: Immunophenotypic and genomic characteristics clinical features and outcome in 38 adults and 26 children
40. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: Correlation with specific genotype. I. ETV6/AML1 ALLs identification
41. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10 CD34 CD13 and CD38 expresssion
42. Differential TdT expression in acute leukemia by flow cytometry: A quantitative study
43. A clinical laboratory approach to the evaluation of terminal deoxynucleotidyl transferase (TdT) by flow cytometry (FCM)
44. Flow cytometric terminal deoxynucleotidyltransferase analysis. Evaluation of Triton X-100 and methanol permeabilization methods compared with immunofluorescence microscopy
45. A novel rapid multiparametric approach for flow cytometric analysis of intranuclear terminal deoxynucleotidyl transferase
46. Flow cytometric analysis of terminal deoxynucleotidyl transferase. A simplified method
47. Detection of terminal deoxynucleotidyl transferase (TdT) by flow cytometry in leukemic disorders
48. Comparison of outcome clinical laboratory and immunological features in 164 children and adults with T-ALL
49. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies
50. Functionally different T-lymphocytic subpopulations determined by their sensitivity to complement-dependent cell lysis with the monoclonal antibody 4A
51. CD7+ acute non-lymphocytic leukemia: Evidence for an early multipotential progenitor
52. Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies
53. Natural killer cell acute leukemia with myeloid antigen expression. A previously undescribed form of acute leukemia
54. Leukaemia of natural killer cell large granular lymphocyte type with HLA-DR-CD16-CD56bright+ phenotype
55. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity
56. HLA-DR- CD33+ CD56+ CD16-myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3
57. Natural killer cell precursor acute lymphoma/leukemia presenting in an infant
58. Natural killer (NK) cell leukaemia in a patient with a B cell non-Hodgkin's lymphoma
59. Blast crisis of chronic myelogenous leukemia exhibiting immunophenotypic features of a myeloid/natural killer cell precursor
60. Secondary myeloid/natural killer cell precursor acute leukemia following essential thrombocythemia
61. Aggressive natural killer-like T-cell malignancy with leukemic presentation following solid organ transplantation
62. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia
63. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma
64. Natural killer lymphocyte blast crisis of chronic myelogenous leukemia
65. CD3+ CD4- CD8-large granular T-cell lymphoproliferative disorder
66. An acute form of T gamma lymphoproliferative disease presenting with massive splenomegaly-importance of immunophenotyping for diagnosis
67. Proposals for the immunological classification of acute leukemias
68. Correlation of morphological FAB classification and immunophenotyping: Value in recognition of morphological cytochemical and immunological characteristics of mixed leukaemias
69. Flow cytometry in the diagnosis of acute leukemia
70. Acute leukemia and related entities. Impact of new technology
71. Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: Implications for clinical trials
72. The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia
73. Classifying acute leukemia by immunophenotyping: A combined FAB-immunologic classification of AML
74. A new approach of acute lymphoblastic leukemia immunophenotypic classification: 1984-1994 The GEIL experience
75. Multiple lineage reactivity in childhood leukemia
76. Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia
77. Acute biphenotypic leukaemia: Immunophenotypic and cytogenetic analysis
78. Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating for minimal residual disease in acute leukemia and high-risk myelodysplastic syndrome
79. Immunophenotypic aberrance in adult acute lymphoblastic leukemia
80. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted action investigation of minimal residual disease in acute leukemia: International standardization and clinical evaluation
81. Childhood leukemias
82. Cytogenetically aberrant cells are present in the CD34+CD33-38-19-marrow compartment in children with acute lymphoblastic leukemia
83. When is acute lymphoblastic leukemia biphenotypic hybrid mixed lineage or biclonal?
84. Lineage promiscuity in hemopoietic differentiation and leukemia
85. Immunophenotyping in the classification of acute leukemia in adults. Interpretation of multiple lineage reactivity
86. Biphenotypic acute leukemia in adults
87. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): Immunophenotypic ultrastructural cytogenetic and molecular characteristics
88. Acute lymphoblastic leukemia. Survey of immunophenotype French-American-British classification frequency of myeloid antigen expression and karyotypic abnormalities in 210 pediatric and adult cases
89. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience
90. The diagnostic and prognostic value of immunophenotyping in acute leukemia
91. Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations
92. Cytogenetic findings in acute biphenotypic leukaemia
93. Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia
94. CD33+ B-cell precursor acute lymphoblastic leukemia in children: A distinct subgroup of B-cell precursor acute lymphoblastic leukemia
95. Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia
96. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood
97. CD2 + CD19 + acute lymphoblastic leukaemia in 16 children and adults: Clinical and biological features
98. Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: A Children's Cancer Group study
99. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues
100. Lineage heterogeneity in acute leukaemia: Acute mixed-lineage leukaemia and lineage switch
101. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)
102. Acute myeloid and T-cell acute lymphoblastic leukaemia with aberrant antigen expression exhibit similar TCRdelta gene rearrangements
103. CD7 CD4 and myeloid antigen-positive acute lymphoblastic leukemia
104. Hematogones in the bone marrow of adults. Immunophenotypic features clinical settings and differential diagnosis
105. Hematogones: A multiparameter analysis of bone marrow precursor cells
106. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology immunophenotype adhesion molecule expression and architectural features
107. Terminal deoxynucleotidyl transferase (TdT)positive cells in bone marrow in the absence of hematologic malignancy
108. The presence of CD34+ cell clusters predicts impending relapse in children with acute lymphoblastic leukemia receiving maintenance chemotherapy
109. Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry
110. The mechanisms involved in the impairment of hematopoiesis in autologous bone marrow transplantation
111. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients
112. Discrete clusters of hematopoietic cells in the marrow cavity of man after bone marrow transplantation
113. Clonal hematopoiesis demonstrated by X-linked DNA polymorphisms after allogeneic bone marrow transplantation
114. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: Differential effects of growth factor type and role of CD34(+) cell dose
115. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow mobilized peripheral blood and fetal liver
116. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion
117. Allogeneic peripheral blood stem cell transplantation
118. Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation
119. Assessment of hematologic progenitor engraftment by complete reticulocyte maturation parameters after autologous and allogeneic hematopoietic stem cell transplantation
120. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen
121. Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats
122. Studies of minimal residual disease in acute lymphocytic leukemia
123. Detection of minimal residual disease in acute leukemia patients
124. Monitoring minimal residual disease in acute leukemia: Expectations possibilities and initial clinical results
125. Detection of minimal residual disease
126. Minimal residual disease detection by flow cytometry: Can it serve as a predictor of future relapse?
127. Detection of minimal residual disease in acute leukemia
128. Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry
129. Applications of cytometry to study acute leukemia: In vitro determination of drug sensitivity and detection of minimal residual disease
130. Detection of minimal residual disease in acute lymphoblastic leukemia: The St Jude experience
131. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease
132. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: A study of five cases controlled by genetic methods
133. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry
134. Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry
135. Phenotypic analysis ofCD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease
136. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC)
137. Acute lymphoblastic leukemia (ALL): Detection of minimal residual disease (MRD) at flow cytometry
138. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse
139. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection
140. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
141. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies
142. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
143. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
144. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation
145. Childhood acute lymphoblastic leukemia: Are routine endof-therapy bone marrow and cerebrospinal fluid examinations necessary?
146. Association of immunophenotype with cerebrospinal fluid involvement in childhood B-lineage acute lymphoblastic leukemia
147. Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis
148. Flow cytometry and the study of central nervous disease in patients with acute leukaemia
149. Terminal deoxynucleotidyl transferase (TdT)positive cells in cerebrospinal fluid and development of overt CNS leukemia: A 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma
150. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia
151. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse
152. Morphologic immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: A Pediatric Oncology Group study
153. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features
154. Therapy and prognostic factors in adult acute lymphoblastic leukaemia
155. Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): Experience of the German Multicentre Trials ALL-BFM and GMALL
156. Prognostic factors in childhood acute lymphoblastic leukemia
157. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia
158. CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10(+strong) and CD10(+weak) common acute lymphoblastic leukemia
159. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: A report from the Children's Cancer Group
160. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study
161. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features
162. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis
163. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: Experience of the BFM study 86
164. Adult and childhood acute lymphoblastic leukemia: Clinico-biological differences based on CD34 antigen expression
165. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia
166. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL
167. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
168. Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia
169. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood
170. Adult biphenotypic acute leukaemia: An entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression
171. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome
172. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 8364
173. Characterization of multidrug resistance by fluorescent dyes
174. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells
175. Multidrug resistance and P-glycoprotein expression
176. Multidrug resistance
177. The MDR1 gene responsible for multidrug-resistance codes for P-glycoprotein
178. Multidrug resistance (MDR) in cancer. Mechanisms reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
179. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: No evidence of prognostic impact in follow-up
180. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
181. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy relapse rate and overall survival in acute leukemia
182. MDR1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques
183. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells
184. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia
185. Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: Comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines
186. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods
187. Multicentric evaluation of the MDR phenotype in leukemia
188. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA
189. DNA aneuploidy in adult acute leukemia
190. Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia
191. Analysis of the cellular DNA and RNA content in acute leukemias by flow cytometry
192. Frequency and clinical significance of DNA aneuploidy in acute leukemia
193. DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: Correlation of FAB classification with DNA stemline and proliferation
194. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood
195. Identification of L3 leukemia and Burkitt's lymphoma cells by flow cytometric quantitation of nuclear and cellular RNA and DNA content
196. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia
197. Bcl-2 expression and prognosis in childhood acute leukemia
198. CD95's deadly mission in the immune system
199. CD95(APO-1/Fas)-mediated apoptosis: Live and let die
200. Death the Fas way: Regulation and pathophysiology of CD95 and its ligand
201. ALPS an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis
202. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
203. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells
204. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients
205. New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens
206. The tetraspanin superfamily: Molecular facilitators
207. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: A Pediatric Oncology Group study
208. Expression of adhesion molecules in childhood B-lineage-cell neoplasms
209. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study
210. CD7+ CD4- CD8-acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells
211. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse
212. Immunophenotype of adult acute lymphoblastic leukemia clinical parameters and outcome: An analysis of a prospective trial including 562 tested patients (LALA87)
213. Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma
214. T-cell receptor tau delta +/CD3+4-8-T-cell acute lymphoblastic leukemias: A distinct subgroup of leukemias in children. A report of five cases
215. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis
216. The immunophenotype in infant acute lymphoblastic leukaemia: Correlation with clinical outcome. An Italian multicentre study (AIEOP)
217. The role of immunophenotype in acute lymphoblastic leukemia of infant age
218. Adult acute lymphocytic leukemia: Critical review of current knowledge
219. Acute lymphocytic leukemia in adults: An update
220. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period
221. Immunophenotyping of congenital leukemia
222. Congenital leukemia: Report of two cases
223. Simplified immunophenotypic analysis by laser scanning cytometry
224. Immunophenotypic analysis of hematologic malignancy by laser scanning cytometry
225. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray
226. Lineage commitment in biphenotypic leukemia
227. Asynchronous antigen expression in B-lineage acute lymphoblastic leukemia